Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6967970 | 0.89 | ALDH1A1 (0.39) | ALDH1A1CALM1TAAR1HRH3HTR2B | |
| SCHEMBL9029161 | 0.88 | TSHR (0.48) | ALDH1A1CALM1TAAR1HRH3HTR2B | |
| SCHEMBL4629510 | 0.85 | TAAR1 (0.40) | ALDH1A1TAAR1METRAB9ASMN1; SMN2 | |
| SCHEMBL2102562 | 0.84 | HRH3 (0.51) | ALDH1A1HRH3RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL4628344 | 0.83 | GABRA1 (0.35) | ALDH1A1TAAR1HTR2BRAB9ASMN1; SMN2 | |
| Immethridine SCHEMBL845141 | 0.82 | HRH4 (0.44) | ALDH1A1HRH3SMN1; SMN2HRH4CYP1A2 | |
| SCHEMBL1753940 | 0.82 | KCNH2 (0.50) | ALDH1A1TAAR1HRH3RAB9ATDP1 | |
| SCHEMBL31060957 | 0.81 | HRH3 (0.55) | HRH3HRH4CYP2D6 | |
| SCHEMBL3149298 | 0.80 | L3MBTL1 (0.49) | ALDH1A1HRH3RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL6971279 | 0.80 | HRH3 (0.38) | TAAR1HRH3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11439624-B2 | Promoting sleep using AT1 receptor blockers | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-09-13 | — | — | US | claimed |
| CN-110234718-A | Wear-resistant coating composition with inorganic metal oxide | 莫门蒂夫性能材料股份有限公司 | 2019-09-13 | — | — | CN | claimed |
| CN-108368494-A | Methods, compositions and uses of novel FYN kinase inhibitors | 沃伦·C·刘 | 2018-08-03 | — | — | CN | claimed |
| WO-2013119605-A1 | PROMOTING SLEEP USING AT1 RECEPTOR BLOCKERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-08-15 | — | — | WO | claimed |
| CN-101374832-B | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE | 2013-03-06 | — | — | CN | claimed |
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | claimed |
| CN-101374832-A | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | claimed |
| EP-1981880-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | claimed |
| JP-1203366-A | — | — | None | — | — | JP | disclosed |
| US-11439624-B2 | Promoting sleep using AT1 receptor blockers | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-09-13 | — | — | US | disclosed |
| CN-108573823-A | Thin film switch | 上海锦昀电子科技有限公司 | 2018-09-25 | — | — | CN | disclosed |
| US-9580431-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9580431-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-28 | — | — | US | disclosed |
| US-4814343-A | ANTIISCHEMIC | U C B, S.A. (BE) | 1989-03-21 | — | — | US | disclosed |
| EP-0269599-A2 | Substituted 1H-imidazoles | U C B, S.A. (BE) | 1988-06-01 | — | — | EP | disclosed |
| EP-0024829-B1 | 4-BENZYL- AND 4-BENZOYLIMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Farmos-Yhtyma Oy (FI) | 1984-04-25 | — | — | EP | disclosed |
| US-4443466-A | DIURETICS, SEDATIVES, ANALGESICS | Farmos-Yhtyma OY (Farmos Group Ltd.) (FI) | 1984-04-17 | — | — | US | disclosed |
| EP-0024829-A1 | 4-Benzyl- and 4-benzoylimidazole derivatives, processes for their preparation and pharmaceutical compositions comprising the same | Farmos-Yhtyma Oy (FI) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | CRY1, GPR119, MTNR1A | ALDH1A1 351/4885CALM1 2294/4885TAAR1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.